C9082 HCPCS Level II code: Injection, dostarlimab-gxly, 100 mg
CMS terminated C9082: its last date of service was Dec 31, 2021. It stays here for looking up older claims; newer services need a current code.
Official description
C9082Injection, dostarlimab-gxly, 100 mg
Short description: Inj dostarlimab-gxly, 100 mg
HCPCS · United States
Medicare details
The indicators CMS publishes with C9082 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Special coverage instructions apply
- Medicare pricing
- Statute
- Type of service
- Other medical items or services; Ambulatory surgical center (facility usage for surgical services)
- BETOS category
- Chemotherapy
- Coverage statute
- 1833(t)
- Cross-reference
- See J9272
- Added
- Oct 1, 2021
- Terminated after
- Dec 31, 2021
Where C9082 sits
- 1C codesOutpatient prospective payment system
- 2Terminated C9082Injection, dostarlimab-gxly, 100 mg
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
Is HCPCS code C9082 still valid?
No. CMS terminated C9082; its last date of service was Dec 31, 2021. It is listed for looking up services from before then. Use a current code for newer services.
Does Medicare cover C9082?
CMS lists C9082’s Medicare coverage as “Special coverage instructions apply” and its pricing as “Statute”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside C9082
All C codesC9076Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic doseC9077Injection, cabotegravir and rilpivirine, 2mg/3mgC9078Injection, trilaciclib, 1 mgC9079Injection, evinacumab-dgnb, 5 mgC9080Injection, melphalan flufenamide hydrochloride, 1 mgC9081Idecabtagene vicleucel, up to 460 million autologous anti-bcma car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic doseC9083Injection, amivantamab-vmjw, 10 mgC9084Injection, loncastuximab tesirine-lpyl, 0.1 mgC9085Injection, avalglucosidase alfa-ngpt, 4 mgC9086Injection, anifrolumab-fnia, 1 mgC9087Injection, cyclophosphamide, (auromedics), 10 mgC9088Instillation, bupivacaine and meloxicam, 1 mg/0.03 mg